Which class of drugs does selumetinib belong to? Is it a targeted therapy drug?

Selumetinib (Selumetinib) is an oral small molecule kinase inhibitor mainly used to treat tumor diseases driven by certain specific gene mutations. Its mechanism of action is to inhibit the MEK1 and MEK2 kinases in the RAS-RAF-MEK-ERK signaling pathway, blocking the abnormal proliferation and survival signals of tumor cells, thereby achieving the effect of inhibiting tumor growth.

From a drug classification perspective, selumetinib is a targeted therapy drug. Targeted therapy means that drugs act on specific molecules or signaling pathways in tumor cells. Compared with traditional chemotherapy, targeted drugs are more precise and have relatively fewer side effects. Selumetinib selectively inhibits MEK kinase, targets and regulates intracellular signaling pathways, and blocks abnormal cell proliferation. It is suitable for patients with tumors containing RAS or BRAF mutations.

Clinically, selumetinib is primarily approved for the treatment of unresectable neurofibromas caused by neurofibromatosis, particularly in children and adolescents, and as adjuvant treatment of certain advanced solid tumors. It shows good efficacy and tolerability during treatment, and especially plays an important role in inhibiting tumor progression and improving patients' quality of life.

To sum up, selumetinib is a typical targeted therapy drug that focuses on intervening in key signaling pathways of tumor cells. Its precise mechanism of action gives the drug significant advantages in the treatment of tumors with related gene mutations, making it an effective treatment option for many patients.

Reference materials:https://www.drugs.com/